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In our recent publication,1 we have described the discovery 
of the role of Dedicator of Cytokinesis 4 (DOCK4) as a poten-
tial biomarker protein predictive of bone metastasis within 
breast cancer. Bone is a common site of metastasis within 
advanced breast cancer, and over 70% of advanced breast cancer 
patients develop bone metastases.2 Patients present with symp-
toms of bone metastasis in many cases years after apparently 
successful treatment, with disseminated tumour cells remain-
ing dormant within bone prior to their activation. The cellular 
mechanisms leading to both breast cancer metastasis to bone, 
and the eventual reactivation of dormant breast cancer cells, are 
currently the subject of intensive research. Bone is the subject 
of constant turnover with bone homeostasis being regulated by 
the activity of bone-resorbing osteoclasts and bone-forming 
osteoblasts.3 Disseminated and reactivated breast cancer cells 
secrete parathyroid hormone–related protein (PTHrP), which 
triggers osteoblasts to increase their synthesis and secretion of 
receptor activator of NF-κB ligand (RANKL), as well as 
reduce their secretion of osteoprotegerin (OPG) (an orphan 
receptor for RANKL). This results in increased binding of 
RANKL to the receptor for RANKL (RANK) resulting in 
osteoclast activation and bone destruction. Degradation of 
bone releases growth factors trapped in the bone matrix, which 
in turn stimulate breast cancer cell proliferation and release of 
PTHrP, resulting in a ‘vicious cycle’ of bone destruction.4
Current treatments for bone metastasis within breast cancer 
include bisphosphonate drugs (such as zoledronic acid)5 and 
antibody-based therapies, eg, denosumab.6 These treatments 
have greatly improved patient quality of life, with zoledronic 
acid conferring a statistically significant improvement in inva-
sive disease–free survival within women who were >5 years 
post-menopausal.7 Despite these improvements in patient 
treatment, these drugs are not without side effects, including 
the case of bisphosphonate treatment of osteonecrosis of the 
jaw.8 To date, there are no effective biomarkers available to pre-
dict which patients are at greatest risk of developing bone 
spread, enabling a personalised medicine approach towards the 
treatment of skeletal metastasis within breast cancer.
We are engaged in research aiming to elucidate the molecu-
lar basis of cancer spread to the skeleton. This work has bene-
fitted from access to unique patient sample banks, including 
samples from the large, open-label, international, multicentre, 
randomised, controlled, parallel-group phase 3 trial AZURE, 
which asks the question ‘Does adjuvant zoledronic acid reduce 
recurrence in patients with high risk localised breast cancer?’. 
The AZURE trial has provided both tissue samples (tissue 
microarrays) as well as patient serum and plasma samples from 
patients receiving standard adjuvant therapy either with or 
without addition of zoledronic acid. In addition, proteomic 
methods have been used to characterise murine models of 
breast cancer spread to bone, including intracardiac injection 
models of bone metastasis.9 Our proteomic analysis of bone-
homing and parental triple negative breast cancer cells derived 
from intracardiac injection murine models has identified a 
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panel of potential bone metastasis biomarker candidates 
including macrophage actin-capping protein (CapG), the 
PDZ-domain containing adaptor protein GIPC1,10 and the 
cell motility regulator DOCK4.1
DOCK4 was identified as a potential biomarker predicting 
bone metastasis risk via quantitative proteomic analysis of 
bone-homing and parental MDA-MB-231 cells using stable 
isotope labelling by amino acids in cell culture (SILAC).1,11,12 
DOCK4 expression was elevated 2.5-fold within bone homing 
cells and was not elevated within a lung-homing control cell 
line, suggesting bone specificity. Immunohistochemical assess-
ment of DOCK4 expression levels within AZURE-patient 
derived tissue microarrays (n = 689) demonstrated that 
DOCK4 levels were significantly prognostic for first recur-
rence within bone in control arm standard chemotherapy) 
patients (hazard ratio [HR]: 2.13, 95% confidence interval 
[CI[: 1.06-4.30, P = .034), an effect not observed within the 
zoledronate treatment arm (HR: 0.812, 95% CI: 0.176-3.76, 
P = .790).1 There was no association of DOCK4 levels with 
metastatic spread to nonbone sites suggesting that DOCK4 
levels within primary breast tumours predict aggressive disease 
and risk of metastasis specifically to bone. The absence of a 
predictive effect within the zoledronate-treated arm suggests 
that DOCK4 levels may also inform patient treatment deci-
sions.1 There was no statistically significant difference in over-
all survival between patients with high and low DOCK4 levels 
within this study.
Our study aimed primarily to look into the role of DOCK4 
as a potential predictive marker for bone metastasis. Within 
our study, high DOCK4 levels reduced the incidence of non-
skeletal metastases within patients in the control arm of the 
AZURE trial.1 This effect was not observed within the zole-
dronic acid treatment arm, suggesting that zoledronate may 
remove an advantageous effect of high DOCK4 levels upon 
the incidence of nonskeletal metastases. The mechanism of 
action of zoledronate on nonbone metastases is currently 
unknown; however, it has been previously described that zole-
dronic acid can inhibit the proliferation, survival, and migra-
tion of breast cancer cells.13 DOCK4 levels may therefore have 
prognostic potential for nonskeletal as well as skeletal 
metastases.
The role of DOCK4 as a prognostic biomarker for meta-
static spread to bone was a unique finding within our published 
study. DOCK4 is a known guanine nucleotide exchange factor 
(GEF) responsible for activation of several GTPases inside the 
cell, including the GTPase protein Rac1, a pivotal regulator of 
cell migration expressed at the leading edge of motile cells.14 
The mechanism of action of DOCK4 within the regulation of 
cell migration is still the subject of active research. Previous 
studies have demonstrated that the proangiogenic growth fac-
tor vascular endothelial growth factor (VEGF) promotes the 
interaction of DOCK4 with DOCK9 (a GEF for the GTPase 
Cdc42).15 In addition, VEGF-dependent Rac activation by 
DOCK4 is required for the activation of the GTPase Cdc42, 
and VEGF-dependent Rac activation is itself dependent on 
the activation of a further GTPase RhoG.15 In this way, the 
activity of a GTPase signalling cascade functions to both acti-
vate DOCK4 and transduce signals downstream of this impor-
tant GEF. DOCK4 activation leads to the formation of lateral 
filopodia within epithelial cells within tumours, and the forma-
tion of blood vessel lumen within tumour angiogenesis.15 
DOCK4 thus plays a pivotal role within tumour angiogenesis; 
however, its precise role within bone-specific metastasis is still 
to be elucidated.
While elucidating the role of DOCK4 within cancer spread 
to bone, we must be aware that proteins often play pleiotropic 
roles within the cell. Research within our group previously 
identified actin capping protein (CapG) as a prognostic bio-
marker for risk of breast cancer spread to bone. Actin-capping 
proteins do not appear to offer an obvious bone-specific func-
tion for metastatic spread; however, subsequent research 
revealed that CapG can act as an epigenetic regulator responsi-
ble for the increased expression of a prometastatic gene stanni-
ocalcin-I (STC-I), required for metastasis to bone.16 Discovered 
biomarker proteins may thus achieve their effects via functions 
that differ from the primary gene annotation, and, thus, the 
pro–bone-metastatic role of DOCK4 may involve additional 
functions to the regulation of cell motility via GTPases.
The expression of DOCK4 is induced by the cytokine 
transforming growth factor-β (TGFβ), a pivotal cytokine 
within bone metastasis.17 TGFβ acts via Smad phosphoryla-
tion to increase the expression of numerous gene products, 
including c-MAF, a transcription factor responsible for pro-
moting bone metastasis within breast cancer.18 Previous 
research within our group has also identified GIPC1 (a scaf-
folding protein and binding partner of the TGFβ receptor) as 
a potential biomarker prognostic for increased risk of bone 
metastasis within breast cancer.10 DOCK4 expression levels 
may thus be positively correlated with the expression levels of 
c-MAF,19 suggesting that, within bone metastasis of breast 
cancer, TGFβ increases expression of both c-MAF and 
DOCK4. DOCK4 may thus act as a functional mediator of a 
c-MAF response panel. The precise role of DOCK4 function 
within metastasis to bone is still to be elucidated. Studies con-
ducted within our laboratory demonstrated that stable knock-
down of DOCK4 expression reduced breast cancer cell 
motility; however, this effect was transient, being significant at 
6 hours post knockdown, but not observed as significant levels 
12 hours post knockdown.1 Cell motility may be the only 
aspect of DOCK4’s role that is altered in bone metastasis of 
breast cancer.
Our research to date has clearly identified a series of pro-
teins with elevated expression specifically within bone metasta-
sis of breast cancer. Functional study of these proteins has 
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identified that they are frequently downstream of key cytokines 
and growth factors within skeletal metastasis, including TGFβ. 
We anticipate that DOCK4 will be just one protein within a 
panel of proteins ultimately forming a prognostic test for clini-
cal application. Multiprotein tests have greater utility for 
informing patient treatment than single-protein tests,20 and 
have a greater ability to deal with diseases with known molecu-
lar heterogeneity, such as breast cancer. Research efforts are 
therefore currently underway to further supplement our pro-
tein panel with additional proteins, thus increasing the sensi-
tivity and specificity of this clinical test when eventually 
applied. There are many aspects of DOCK4’s role within bone 
metastasis of breast cancer, which remain to be elucidated, 
including the possible role of DOCK4 within nonbone metas-
tasis, as well as the interaction of DOCK4 with bisphospho-
nate treatment and its potential role as an informative 
biomarker for patient treatment decisions.
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